Market Closed -
Nasdaq
21:00:00 08/05/2024 BST
|
5-day change
|
1st Jan Change
|
21.7
USD
|
-1.56%
|
|
+1.88%
|
+259.87%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
82.31
|
56.12
|
143.9
|
857.1
|
-
|
-
|
Enterprise Value (EV)
1 |
-24.41
|
-11.47
|
143.9
|
590.1
|
537.1
|
509.1
|
P/E ratio
|
-2.53
x
|
-1.27
x
|
-2.52
x
|
-11.6
x
|
-9.5
x
|
-8.2
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
400
x
|
-
|
177
x
|
EV / Revenue
|
-
|
-
|
-
|
275
x
|
-
|
105
x
|
EV / EBITDA
|
0.88
x
|
0.26
x
|
-2.53
x
|
-8.49
x
|
-6.52
x
|
-5.14
x
|
EV / FCF
|
-
|
0.3
x
|
-
|
-10.3
x
|
-5.88
x
|
-5.2
x
|
FCF Yield
|
-
|
332%
|
-
|
-9.74%
|
-17%
|
-19.2%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
16,867
|
17,215
|
23,857
|
38,880
|
-
|
-
|
Reference price
2 |
4.880
|
3.260
|
6.030
|
21.70
|
21.70
|
21.70
|
Announcement Date
|
03/03/22
|
02/03/23
|
12/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
2.143
|
-
|
4.834
|
EBITDA
1 |
-
|
-27.84
|
-44.79
|
-56.75
|
-69.47
|
-82.42
|
-99.05
|
EBIT
1 |
-
|
-27.84
|
-44.8
|
-56.76
|
-75.24
|
-101
|
-124.6
|
Operating Margin
|
-
|
-
|
-
|
-
|
-3,511.33%
|
-
|
-2,577.42%
|
Earnings before Tax (EBT)
1 |
-
|
-27.8
|
-43.94
|
-54.42
|
-66.07
|
-93.53
|
-113.9
|
Net income
1 |
-14.4
|
-27.8
|
-43.94
|
-54.42
|
-66.07
|
-93.53
|
-120
|
Net margin
|
-
|
-
|
-
|
-
|
-3,083.31%
|
-
|
-2,481.4%
|
EPS
2 |
-5.220
|
-1.930
|
-2.560
|
-2.390
|
-1.863
|
-2.284
|
-2.646
|
Free Cash Flow
1 |
-
|
-
|
-38.06
|
-
|
-57.45
|
-91.4
|
-97.95
|
FCF margin
|
-
|
-
|
-
|
-
|
-2,681%
|
-
|
-2,026.09%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
19/02/21
|
03/03/22
|
02/03/23
|
12/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
2.143
|
-
|
-
|
-
|
EBITDA
1 |
-
|
-9.619
|
-11.56
|
-11.88
|
-11.73
|
-11.96
|
-15.64
|
-13.58
|
-15.57
|
-18.11
|
-16.61
|
-17.17
|
-17.58
|
-19.87
|
-
|
EBIT
1 |
-8.794
|
-9.62
|
-11.57
|
-11.88
|
-11.73
|
-11.96
|
-15.64
|
-13.58
|
-15.57
|
-18.11
|
-18.12
|
-19.35
|
-20.57
|
-19.87
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-903.08%
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-8.773
|
-9.597
|
-11.41
|
-11.6
|
-11.34
|
-11.46
|
-15
|
-12.93
|
-15.03
|
-14.99
|
-15.86
|
-17.16
|
-18.45
|
-15
|
-
|
Net income
1 |
-8.773
|
-9.597
|
-11.41
|
-11.6
|
-11.34
|
-11.46
|
-15
|
-12.93
|
-15.03
|
-14.99
|
-15.86
|
-17.16
|
-18.45
|
-15
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-800.97%
|
-
|
-
|
-
|
EPS
2 |
-0.5200
|
-0.5600
|
-0.6700
|
-0.6800
|
-0.6600
|
-0.5600
|
-0.6500
|
-0.5500
|
-0.6200
|
-0.4200
|
-0.4377
|
-0.4182
|
-0.5086
|
-0.5353
|
-0.6450
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
03/03/22
|
05/05/22
|
04/08/22
|
03/11/22
|
02/03/23
|
09/05/23
|
03/08/23
|
02/11/23
|
12/03/24
|
02/05/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
107
|
67.6
|
-
|
267
|
320
|
348
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-38.1
|
-
|
-57.5
|
-91.4
|
-98
|
ROE (net income / shareholders' equity)
|
-
|
-35.5%
|
-53.3%
|
-
|
-34.6%
|
-26.4%
|
-39.4%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
0.02
|
-
|
-
|
-
|
2.5
|
2.5
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
51.71%
|
Announcement Date
|
19/02/21
|
03/03/22
|
02/03/23
|
12/03/24
|
-
|
-
|
-
|
Last Close Price
22.04
USD Average target price
42
USD Spread / Average Target +90.52% Consensus |
1st Jan change
|
Capi.
|
---|
| +259.87% | 857M | | +2.93% | 106B | | +7.02% | 23.47B | | -14.60% | 21.9B | | -7.05% | 18.77B | | -38.55% | 17.85B | | -8.83% | 16.78B | | +5.51% | 14.41B | | +37.49% | 12.86B | | +329.39% | 8.78B |
Bio Therapeutic Drugs
|